Post-Exposure Therapeutic Efficacy of COX-2 Inhibition against Burkholderia pseudomallei

PLoS Neglected Tropical Diseases

Volumn 7, Issue 5, 2013, Pages

  Asakrah, Saja ^a   Nieves, Wildaliz ^a   Mahdi, Zaid ^a   Agard, Mallory ^a   Zea, Arnold H ^b   Roy, Chad J ^c   Morici, Lisa A ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; CYCLOOXYGENASE 2; N (2 CYCLOHEXYLOXY 4 NITROPHENYL) METHANESULFONAMIDE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NITRIC OXIDE; PROSTAGLANDIN E2; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL VIRULENCE; BURKHOLDERIA PSEUDOMALLEI; CONTROLLED STUDY; DENSITOMETRY; DISEASE COURSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE DEFICIENCY; LUNG INFECTION; MACROPHAGE; MELIOIDOSIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL; WEIGHT REDUCTION; WESTERN BLOTTING;

EID: 84878519661     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002212     Document Type: Article

References (51)

1. Cheng AC, Currie BJ, (2005) Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 18: 383-416.
2. Larsen JC, Johnson NH, (2009) Pathogenesis of Burkholderia pseudomallei and Burkholderia mallei. Mil Med 174: 647-651.
3. Inglis TJJ, (2010) The Treatment of Melioidosis. Pharmaceuticals 3: 1296-1303.
4. Wiersinga WJ, Currie BJ, Peacock SJ, (2012) Melioidosis. N Engl J Med 367: 1035-1044.
5. Cheng AC, Limmathurotsakul D, Chierakul W, Getchalarat N, Wuthiekanun V, et al. (2007) A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. Clin Infect Dis 45: 308-314.
6. Goodyear A, Kellihan L, Bielefeldt-Ohmann H, Troyer R, Propst K, et al. (2009) Protection from pneumonic infection with burkholderia species by inhalational immunotherapy. Infect Immun 77: 1579-1588.
7. Rozak DA, Gelhaus HC, Smith M, Zadeh M, Huzella L, et al. (2010) CpG oligodeoxyribonucleotides protect mice from Burkholderia pseudomallei but not Francisella tularensis Schu S4 aerosols. J Immune Based Ther Vaccines 8: 2.
8. Judy BM, Taylor K, Deeraksa A, Johnston RK, Endsley JJ, et al. (2012) Prophylactic application of CpG oligonucleotides augments the early host response and confers protection in acute melioidosis. PLoS One 7: e34176.
9. Easton A, Haque A, Chu K, Patel N, Lukaszewski RA, et al. (2011) Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis. J Infect Dis 204: 636-644.
10. Warner TD, Mitchell JA, (2004) Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 18: 790-804.
11. Weischenfeldt J, Porse B, (2008) Bone Marrow-Derived Macrophages (BMM): Isolation and Applications. CSH Protoc 2008: pdb prot5080.
12. Burtnick MN, Brett PJ, Nair V, Warawa JM, Woods DE, et al. (2008) Burkholderia pseudomallei type III secretion system mutants exhibit delayed vacuolar escape phenotypes in RAW 264.7 murine macrophages. Infect Immun 76: 2991-3000.
13. Brett PJ, DeShazer D, Woods DE, (1998) Burkholderia thailandensis sp. nov., a Burkholderia pseudomallei-like species. Int J Syst Bacteriol 48 Pt 1: 317-320.
14. Stevens JM, Ulrich RL, Taylor LA, Wood MW, Deshazer D, et al. (2005) Actin-binding proteins from Burkholderia mallei and Burkholderia thailandensis can functionally compensate for the actin-based motility defect of a Burkholderia pseudomallei bimA mutant. J Bacteriol 187: 7857-7862.
15. Haraga A, West TE, Brittnacher MJ, Skerrett SJ, Miller SI, (2008) Burkholderia thailandensis as a model system for the study of the virulence-associated type III secretion system of Burkholderia pseudomallei. Infect Immun 76: 5402-5411.
16. West TE, Frevert CW, Liggitt HD, Skerrett SJ, (2008) Inhalation of Burkholderia thailandensis results in lethal necrotizing pneumonia in mice: a surrogate model for pneumonic melioidosis. Trans R Soc Trop Med Hyg 102 Suppl 1: S119-126.
17. Morici LA, Heang J, Tate T, Didier PJ, Roy CJ, (2010) Differential susceptibility of inbred mouse strains to Burkholderia thailandensis aerosol infection. Microb Pathog 48: 9-17.
18. Ceballos-Olvera I, Sahoo M, Miller MA, Del Barrio L, Re F, (2011) Inflammasome-dependent pyroptosis and IL-18 protect against Burkholderia pseudomallei lung infection while IL-1beta is deleterious. PLoS Pathog 7: e1002452.
19. Feterl M, Govan BL, Ketheesan N, (2008) The effect of different Burkholderia pseudomallei isolates of varying levels of virulence on toll-like-receptor expression. Trans R Soc Trop Med Hyg 102 Suppl 1: S82-88.
20. Wiersinga WJ, Wieland CW, Dessing MC, Chantratita N, Cheng AC, et al. (2007) Toll-like receptor 2 impairs host defense in gram-negative sepsis caused by Burkholderia pseudomallei (Melioidosis). PLoS Med 4: e248.
21. West TE, Ernst RK, Jansson-Hutson MJ, Skerrett SJ, (2008) Activation of Toll-like receptors by Burkholderia pseudomallei. BMC Immunol 9: 46.
22. Wiersinga WJ, Dessing MC, van der Poll T, (2008) Gene-expression profiles in murine melioidosis. Microbes Infect 10: 868-877.
23. Serezani CH, Chung J, Ballinger MN, Moore BB, Aronoff DM, et al. (2007) Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase. Am J Respir Cell Mol Biol 37: 562-570.
24. Miyagi K, Kawakami K, Saito A, (1997) Role of reactive nitrogen and oxygen intermediates in gamma interferon-stimulated murine macrophage bactericidal activity against Burkholderia pseudomallei. Infect Immun 65: 4108-4113.
25. Jones-Carson J, Laughlin JR, Stewart AL, Voskuil MI, Vazquez-Torres A, (2012) Nitric oxide-dependent killing of aerobic, anaerobic and persistent Burkholderia pseudomallei. Nitric Oxide.
26. Kalinski P, (2012) Regulation of immune responses by prostaglandin E2. J Immunol 188: 21-28.
27. Gotoh T, Mori M, (1999) Arginase II downregulates nitric oxide (NO) production and prevents NO-mediated apoptosis in murine macrophage-derived RAW 264.7 cells. J Cell Biol 144: 427-434.
28. Chang CI, Liao JC, Kuo L, (2001) Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res 61: 1100-1106.
29. Das P, Lahiri A, Chakravortty D, (2010) Modulation of the arginase pathway in the context of microbial pathogenesis: a metabolic enzyme moonlighting as an immune modulator. PLoS Pathog 6: e1000899.
30. Warawa JM, (2010) Evaluation of surrogate animal models of melioidosis. Front Microbiol 1: 141.
31. Reddy RC, Chen GH, Tateda K, Tsai WC, Phare SM, et al. (2001) Selective inhibition of COX-2 improves early survival in murine endotoxemia but not in bacterial peritonitis. Am J Physiol Lung Cell Mol Physiol 281: L537-543.
32. Ballinger MN, Aronoff DM, McMillan TR, Cooke KR, Olkiewicz K, et al. (2006) Critical role of prostaglandin E2 overproduction in impaired pulmonary host response following bone marrow transplantation. J Immunol 177: 5499-5508.
33. Holt DM, Ma X, Kundu N, Collin PD, Fulton AM, (2012) Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4. J Immunother 35: 179-188.
34. Nokta MA, Pollard RB, (1992) Human immunodeficiency virus replication: modulation by cellular levels of cAMP. AIDS Res Hum Retroviruses 8: 1255-1261.
35. Vancheri C, Mastruzzo C, Sortino MA, Crimi N, (2004) The lung as a privileged site for the beneficial actions of PGE2. Trends Immunol 25: 40-46.
36. Peskar BM, Sawka N, Ehrlich K, Peskar BA, (2003) Role of cyclooxygenase-1 and-2, phospholipase C, and protein kinase C in prostaglandin-mediated gastroprotection. J Pharmacol Exp Ther 305: 1233-1238.
37. Ozaki T, Rennard SI, Crystal RG, (1987) Cyclooxygenase metabolites are compartmentalized in the human lower respiratory tract. J Appl Physiol 62: 219-222.
38. Wiersinga WJ, van der Poll T, (2009) Immunity to Burkholderia pseudomallei. Curr Opin Infect Dis 22: 102-108.
39. Skyberg JA, Rollins MF, Holderness JS, Marlenee NL, Schepetkin IA, et al. (2012) Nasal Acai polysaccharides potentiate innate immunity to protect against pulmonary Francisella tularensis and Burkholderia pseudomallei Infections. PLoS Pathog 8: e1002587.
40. Harbrecht BG, Kim YM, Wirant EA, Simmons RL, Billiar TR, (1997) Timing of prostaglandin exposure is critical for the inhibition of LPS- or IFN-gamma-induced macrophage NO synthesis by PGE2. J Leukoc Biol 61: 712-720.
41. Sadikot RT, Zeng H, Azim AC, Joo M, Dey SK, et al. (2007) Bacterial clearance of Pseudomonas aeruginosa is enhanced by the inhibition of COX-2. Eur J Immunol 37: 1001-1009.
42. Marotta P, Sautebin L, Di Rosa M, (1992) Modulation of the induction of nitric oxide synthase by eicosanoids in the murine macrophage cell line J774. Br J Pharmacol 107: 640-641.
43. Kunkel SL, Wiggins RC, Chensue SW, Larrick J, (1986) Regulation of macrophage tumor necrosis factor production by prostaglandin E2. Biochem Biophys Res Commun 137: 404-410.
44. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, et al. (2005) Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 202: 931-939.
45. Haas AR, Sun J, Vachani A, Wallace AF, Silverberg M, et al. (2006) Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res 12: 214-222.
46. Zhang Z, Reenstra W, Weiner DJ, Louboutin JP, Wilson JM, (2007) The p38 mitogen-activated protein kinase signaling pathway is coupled to Toll-like receptor 5 to mediate gene regulation in response to Pseudomonas aeruginosa infection in human airway epithelial cells. Infect Immun 75: 5985-5992.
47. Uematsu S, Jang MH, Chevrier N, Guo Z, Kumagai Y, et al. (2006) Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c+ lamina propria cells. Nat Immunol 7: 868-874.
48. Hawn TR, Berrington WR, Smith IA, Uematsu S, Akira S, et al. (2007) Altered inflammatory responses in TLR5-deficient mice infected with Legionella pneumophila. J Immunol 179: 6981-6987.
49. Titball RW, (1993) Bacterial phospholipases C. Microbiol Rev 57: 347-366.
50. Rangel Moreno J, Estrada Garcia I, De La Luz Garcia Hernandez M, Aguilar Leon D, Marquez R, et al. (2002) The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis. Immunology 106: 257-266.
51. Woolard MD, Hensley LL, Kawula TH, Frelinger JA, (2008) Respiratory Francisella tularensis live vaccine strain infection induces Th17 cells and prostaglandin E2, which inhibits generation of gamma interferon-positive T cells. Infect Immun 76: 2651-2659.